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The glycogen storage diseases (GSD) are amongst the earliest
recognized inborn errors of metabolism. After the Fulda
Workshop on Glycogen Storage Disease (GSD) type I in
1990, international GSD conferences have been held in
Fulda (2000), Milan (2010), Lyon (2012), and Heidelberg
(2013). Since the start of the internet era, parent-led patient
organizations have pushed for international guidelines for
treatment and follow-up (Phillips 2002). Subsequent interna-
tional collaborative cohort studies have defined the pheno-
types of GSDs and facilitated the development of internation-
ally agreed clinical guidelines. This special edition of the
Journal of Inherited Metabolic Disease discusses highlights
of the International GSD conference held at the University
Medical Center Groningen, the Netherlands, between 15 and
17 June 2017 (IGSD2017). Fifty-three oral presentations, 52
posters, 11 networking sessions, and 2 BMeet the Expert^
sessions attended by 406 participants from 36 countries
reflected the recent progress in individualized and novel ther-
apies, monitoring, and empowerment for patients with
muscle- and/or liver-specific GSD types.
To foster the involvement of all stakeholders, including
parents, in setting the future research agenda, the
International Liver Glycogen Storage Disease Priority
Setting Partnership (IGSD-PSP) (http://igsdpsp.com) was
initiated during the IGSD2017 conference, in collaboration
with the James Lind Alliance (http://www.jla.nihr.ac.uk/).
This partnership aims to identify and prioritize research
addressing current uncertainties about the effects of care and
management. The IGSD-PSP is the first international, multi-
lingual PSP for a group of ultra-rare disorders. The steering
group expects to present the results at the end of 2019.
A highlight of IGSD2017 was the plenary session on
gene therapy, including longitudinal results after gene
therapy in canine GSD Ia models. Ideally, GSD Ia pa-
tients would be no longer dependent on intensive and
unsafe (nocturnal) dietary management after a single
dose of gene therapy. To date, longitudinal, in vivo
functional studies of glucose metabolism in animal
models after gene therapy are lacking. Case histories
of Bmild^ GSD Ia patients have demonstrated that epi-
sodes of hypoglycemia can remain undiagnosed until
patients present with liver adenomas, indirectly empha-
sizing the importance of determining that exogenously
administered genes are stably expressed. Longitudinal
monitoring of GSD Ia patients after gene therapy may
include a combination of (1) assessment of microsomal
glucose-6-phosphatase activities ex vivo (necessitating
invasive liver biopsies), (2) execution of (invasive, clin-
ical) fasting challenges in vivo, (3) advanced continuous
glucose monitoring in the home situation, and (4) appli-
cation of stable isotope methods to longitudinally quan-
tify endogenous glucose production rates in vivo (van
Dijk et al. 2013).
We are delighted to present this special collection of
papers about GSD. Ultra-rare inborn errors of metabo-
lism do not stop at borders between countries or conti-
nents and global collaborations are essential. Clinical
expertise, secure eHealth applications, active patient par-
ticipation, and transparent governance structures includ-
ing all important stakeholders will be fundamental to
improving cross border transfer of knowledge, care,
and cure between professionals and patients, in all pos-
sible directions.
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